{"id":{"repo_id":"milano","oai_identifier":"oai:air.unimi.it:2434/1048754"},"canonical_url":"https://search.dev.ndltd.org/etd/milano/oai:air.unimi.it:2434/1048754","repository":{"repo_id":"milano","name":"Università degli Studi di Milano","base_url":"https://air.unimi.it/oai/request"},"display":{"title":"NOVEL SYNTHETIC PROCESSES FOR THE INDUSTRIAL PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS","abstract":"The project deals with the development of new synthetic processes for the industrial preparation of two emerging active pharmaceutical ingredients (API). Specifically, the process for the preparation of a new paclitaxel prodrug, namely octadecanedioc acid-paclitaxel, was defined. This paclitaxel derivate has shown better results in vivo trials, against a wide range of tumors, in terms of toxicity and efficacy, compared to other conventional formulations of PTX like Abraxane and Cremophor-EL. In order to have an easily scalable process and a final product with high purity a novel synthetic strategy was developed. The second part of the project focused on the development of a process for the industrial preparation of voclosporin, a semi-synthetic analogue of cyclosporin A. This new derivate has been approved for the immunosuppressant medication treatment of Lupus nephritis. A four synthetic steps process was developed to afford the product with the required purity and isomeric composition.","abstract_html":"The project deals with the development of new synthetic processes for the industrial preparation of two emerging active pharmaceutical ingredients (API). Specifically, the process for the preparation of a new paclitaxel prodrug, namely octadecanedioc acid-paclitaxel, was defined. This paclitaxel derivate has shown better results in vivo trials, against a wide range of tumors, in terms of toxicity and efficacy, compared to other conventional formulations of PTX like Abraxane and Cremophor-EL. In order to have an easily scalable process and a final product with high purity a novel synthetic strategy was developed. The second part of the project focused on the development of a process for the industrial preparation of voclosporin, a semi-synthetic analogue of cyclosporin A. This new derivate has been approved for the immunosuppressant medication treatment of Lupus nephritis. A four synthetic steps process was developed to afford the product with the required purity and isomeric composition.","abstract_has_math":false,"creators":["ROSITANO, VINCENZO"],"institution":"Università degli Studi di Milano","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["tutor: A. Bernardi ; co-tutor: L. Senaldi ; coordinatore: D. Passarella","V. Rositano","BERNARDI, ANNA","PASSARELLA, DANIELE"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-05-24","date_published":"2024-05-24","updated_at":"2026-07-27T20:19:03Z","subjects":["API","generic drug","industrial process","Settore CHIM/06 - Chimica Organica"],"languages":["eng"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dx.doi.org/10.13130/rositano-vincenzo_phd2024-05-24","10.13130/rositano-vincenzo_phd2024-05-24"],"render_values":[{"text":"http://dx.doi.org/10.13130/rositano-vincenzo_phd2024-05-24","href":"http://dx.doi.org/10.13130/rositano-vincenzo_phd2024-05-24","code":true},{"text":"10.13130/rositano-vincenzo_phd2024-05-24","href":"https://doi.org/10.13130/rositano-vincenzo_phd2024-05-24","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2434/1048754","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["tutor: A. Bernardi ; co-tutor: L. Senaldi ; coordinatore: D. Passarella","V. Rositano","BERNARDI, ANNA","PASSARELLA, DANIELE"]},{"key":"dc:creator","label":"Author","values":["ROSITANO, VINCENZO"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2024-05-24"]},{"key":"dc:publisher","label":"Institution","values":["Università degli Studi di Milano"]},{"key":"dc:relation","label":"Dc Relation","values":["numberofpages:168"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["API","generic drug","industrial process","Settore CHIM/06 - Chimica Organica"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2434/1048754","http://dx.doi.org/10.13130/rositano-vincenzo_phd2024-05-24","10.13130/rositano-vincenzo_phd2024-05-24"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The project deals with the development of new synthetic processes for the industrial preparation of two emerging active pharmaceutical ingredients (API). Specifically, the process for the preparation of a new paclitaxel prodrug, namely octadecanedioc acid-paclitaxel, was defined. This paclitaxel derivate has shown better results in vivo trials, against a wide range of tumors, in terms of toxicity and efficacy, compared to other conventional formulations of PTX like Abraxane and Cremophor-EL. In order to have an easily scalable process and a final product with high purity a novel synthetic strategy was developed. The second part of the project focused on the development of a process for the industrial preparation of voclosporin, a semi-synthetic analogue of cyclosporin A. This new derivate has been approved for the immunosuppressant medication treatment of Lupus nephritis. A four synthetic steps process was developed to afford the product with the required purity and isomeric composition."]},{"key":"dc:title","label":"Title","values":["NOVEL SYNTHETIC PROCESSES FOR THE INDUSTRIAL PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS"]}]}],"canonical_facts":{"dc:contributor":["tutor: A. Bernardi ; co-tutor: L. Senaldi ; coordinatore: D. Passarella","V. Rositano","BERNARDI, ANNA","PASSARELLA, DANIELE"],"dc:creator":["ROSITANO, VINCENZO"],"dc:date":["2024-05-24"],"dc:description":["The project deals with the development of new synthetic processes for the industrial preparation of two emerging active pharmaceutical ingredients (API). Specifically, the process for the preparation of a new paclitaxel prodrug, namely octadecanedioc acid-paclitaxel, was defined. This paclitaxel derivate has shown better results in vivo trials, against a wide range of tumors, in terms of toxicity and efficacy, compared to other conventional formulations of PTX like Abraxane and Cremophor-EL. In order to have an easily scalable process and a final product with high purity a novel synthetic strategy was developed. The second part of the project focused on the development of a process for the industrial preparation of voclosporin, a semi-synthetic analogue of cyclosporin A. This new derivate has been approved for the immunosuppressant medication treatment of Lupus nephritis. A four synthetic steps process was developed to afford the product with the required purity and isomeric composition."],"dc:identifier":["https://hdl.handle.net/2434/1048754","http://dx.doi.org/10.13130/rositano-vincenzo_phd2024-05-24","10.13130/rositano-vincenzo_phd2024-05-24"],"dc:language":["eng"],"dc:publisher":["Università degli Studi di Milano"],"dc:relation":["numberofpages:168"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:subject":["API","generic drug","industrial process","Settore CHIM/06 - Chimica Organica"],"dc:title":["NOVEL SYNTHETIC PROCESSES FOR THE INDUSTRIAL PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS"],"dc:type":["info:eu-repo/semantics/doctoralThesis"]},"updated_at":"2026-07-27T20:19:03Z"}